Compare INVE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | NYXH |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 126.0M |
| IPO Year | 1997 | 2021 |
| Metric | INVE | NYXH |
|---|---|---|
| Price | $4.01 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 127.7K | 35.7K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $22.10 | $213.98 |
| Revenue Next Year | $20.74 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $2.68 |
| 52 Week High | $5.30 | $8.59 |
| Indicator | INVE | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 19.11 |
| Support Level | $3.17 | N/A |
| Resistance Level | $4.07 | $5.02 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 42.97 | 4.35 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.